Moderna, Inc.
320 Bent Street
Cambridge
Massachusetts
02141
United States
Tel: 617-714-6500
Fax: 617-583-1998
Website: http://www.modernatx.com/
Email: info@modernatx.com
About Moderna, Inc.
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
We have a clear mission to propel the field of mRNA science forward and deliver new medicines to patients and a unique vision for how to achieve this mission.
Our Mission: Deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.
Our Vision: Unlock the potential of mRNA Therapeutics™ by establishing an ecosystem of teams and partners that will work together to develop the broadest possible array of drugs, across diverse therapeutic areas and routes of administration, for serious diseases that are not treatable today.
321 articles with Moderna, Inc.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 21, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
-
Moderna Announces Progress Across Broad Portfolio and all Three Clinical Stage Therapeutic Areas at 2020 R&D Day
9/17/2020
Positive interim analysis from Phase 2 study of CMV vaccine candidate (mRNA-1647); Phase 3 study to begin in 2021 Phase 3 COVE study of COVID vaccine candidate (mRNA-1273) has enrolled 25,296 participants to date; Phase 3 protocol now available online Moderna to enter seasonal flu business given the high medical need for more effective flu vaccine Two-dose regimen of Chikungunya antibody (mRNA-1944) demonstrates the platform’s ability
-
He also said they would be able to deliver 100 million doses to the U.S. government in the “first few months of 2021.”
-
Moderna and Vertex Establish New Collaboration to Treat Cystic Fibrosis Using Gene Editing
9/16/2020
Second collaboration between Moderna and Vertex based on Moderna’s proprietary mRNA and LNP technology Collaboration will leverage Vertex’s investments and capabilities in genetic technologies for CF Moderna to receive $75 million upfront, with potential for additional development, regulatory and commercial milestones and royalty payments CAMBRIDGE & BOSTON, Mass.--( BUSINESS WIRE )-- Moderna, Inc. (Nasdaq:MRNA) and Vertex Pharmace
-
Moderna Announces First Commercial Organization Outside North America in Switzerland
9/16/2020
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, announced the appointment of Dan Staner as Vice President and General Manager, Switzerland.
-
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH)
9/16/2020
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi Farmaceutici S.p.A., an international research-focused healthcare group (Chiesi Group), today announced a collaboration aimed at the discovery and development of mRNA therapeutics for the treatment of pulmonary arterial hypertension (PAH
-
Moderna Names Michael Mullette as Managing Director of New Canadian Subsidiary
9/10/2020
Moderna expands footprint in North America with Canadian subsidiary; permanent presence to support delivery of mRNA vaccines and therapeutics to Canadians CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the appointment of Michael Mullette as Managing Director, Canad
-
Moderna to Present at Upcoming Investor Conferences in September 2020
9/9/2020
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming virtual investor conferences: Morgan Stanley Virtual 18 th Annual Global Healthcare Conference on Monday, September 14, 2020 at 9:00 a.m. ET. Bank of America Virtu
-
The CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Moderna, Novavax, Pfizer, Merck and Sanofi all signed the pledge promising to ensure that any vaccine put forth by one or more of the companies meets the rigorous standards for approval.
-
Biopharma Leaders Unite to Stand with Science
9/8/2020
Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines
-
Moderna to Host Virtual R&D Day on September 17, 2020
9/3/2020
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its fourth annual virtual R&D Day for analysts and investors at 8:00 a.m. ET on Thursday, September 17. Moderna’s R&D Day will include presentations from Stéphane Bancel, Chief Executive Officer,
-
At Least 4 Vaccine Candidates Backed by U.S. Government Predicted to Fail, Analytics Group Says
9/2/2020
The U.S. government has financially backed the development of six different vaccine candidates aimed at the novel coronavirus. Although billions of dollars have been appropriated to the pandemic, at least four of those potential preventative treatments are predicted to fail in the clinic. -
Clinical Catch-Up: August 24-28
8/31/2020
As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look. -
Moderna Confirms Discussions with the Ministry of Health, Labour and Welfare to Supply Japan with 40 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
8/28/2020
Moderna, Inc. confirmed that the Company is engaged in discussions with the Ministry of Health, Labour and Welfare of Japan to potentially purchase 40 million or more doses of mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support Japan’s aim of providing vaccines to the public as soon as possible.
-
Moderna to Present New Interim Clinical Data About mRNA Vaccine Against COVID-19 (mRNA-1273) at Advisory Committee on Immunization Practices (ACIP) Meeting
8/26/2020
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced it is presenting at the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) August Meeting today.
-
Moderna presented more detailed data from the Phase I trial of its mRNA COVID-19 vaccine at the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices today.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 26, 2020.
-
Moderna Confirms Advanced Discussions with European Commission to Supply Europe with 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
8/24/2020
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Company has concluded advanced exploratory talks with the European Commission to supply 80 million doses of mRNA-1273,
-
Moderna signed a contract worth up to $1.525 billion with the U.S. government to supply 100 million doses of mRNA-1273, the company’s experimental COVID-19 vaccine.